Victoria Socha

DocwireNews

Patients with end-stage kidney disease with anemia are commonly treated with recombinant human erythropoietin. However, according to Juan Daniel Diaz Garcia and colleagues at Centro Medico Nacional 20 Noviembre, Mexico City, Mexico, various factors may contribute to possible resistance to this therapy.The researchers conducted a prospective study to evaluate the impact of a structured team approach for the management of anemia in erythropoietin-resistant hemodialysis patients. Results were reported during a poster session at the American Society of Nephrology Kidney Week 2023 in a poster titled Risk Factors Involved in Erythropoietin Resistance in Patients With CKD in a Hemodialysis Unit.During a study period of 18 months, 27 patients were identified as erythropoietin-resistant, defined as erythropoietin &gt;300 units/kg/week. Hemoglobin level, iron indices, parathyroid hormone, and folate, vitamin B12, and reticulocyte counts were determined at baseline and during the study period at 6, 12, and 18 months. Target hemoglobin was 10 to 12 g/dL.A specialized nephrology team evaluated potential factors associated with erythropoietin resistance, and, if necessary, treated every 4 weeks. If the underlying causes of resistance could not be identified or reversed, or if hemoglobin exceeded the target level, downward adjustments of erythropoietin dose of 12.5% to 25% to the nearest 1000 units were considered.The predominant treatable factors associated with erythropoietin resistance were parathyroid hormone levels or iron deficiency. At 4 months, there was a significant decrease in mean erythropoietin dose, from 469 to 319 units/kg/week (P&lt;.001). There was a significant increase in mean hemoglobin level from 10.6 g/dL to 11.6 g/dL (P=.023). At 8 months, patients had erythropoietin doses of less than 300 units/kg/week, reaching target hemoglobin levels.In summary, the authors said, &ldquo;A structured team approach of nephrologists and a monthly adaptation with an individualized management of the patient managed to significantly reduce the dose of erythropoietin with an improvement in serum hemoglobin reaching the objectives set in the international guidelines, identifying and solving the factors involved.&rdquo;Source: Diaz Garcia JD, Maldonado Tapia D, Morales Lopez F, et al. Risk factors involved in erythropoietin resistance in patients with CKD in a hemodialysis unit. TH-PO949. Abstract of a poster presented at the American Society of Nephrology Kidney Week 2023; November 2, 2023; Philadelphia, Pennsylvania.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Identifying and Treating Factors Associated With Erythropoietin Resistance

Anemia and Kidney Disease

Results of a prospective study to evaluate the impact of a structured team approach for the management of anemia in erythropoietin-resistant hemodialysis patients.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe